Fidelis Capital Partners LLC Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Fidelis Capital Partners LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,609 shares of the medical research company’s stock after purchasing an additional 160 shares during the period. Fidelis Capital Partners LLC’s holdings in Amgen were worth $1,331,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of AMGN. Plato Investment Management Ltd lifted its position in shares of Amgen by 7.7% in the 4th quarter. Plato Investment Management Ltd now owns 20,154 shares of the medical research company’s stock worth $5,272,000 after buying an additional 1,446 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Amgen in the fourth quarter worth approximately $1,846,000. Jones Financial Companies Lllp lifted its position in Amgen by 19.2% in the 4th quarter. Jones Financial Companies Lllp now owns 22,300 shares of the medical research company’s stock worth $5,812,000 after buying an additional 3,593 shares in the last quarter. SRS Capital Advisors Inc. grew its position in Amgen by 221.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 2,286 shares of the medical research company’s stock worth $596,000 after acquiring an additional 1,574 shares in the last quarter. Finally, Norden Group LLC raised its stake in shares of Amgen by 5.2% in the 4th quarter. Norden Group LLC now owns 5,548 shares of the medical research company’s stock valued at $1,446,000 after acquiring an additional 275 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This trade represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on AMGN shares. StockNews.com downgraded Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler Companies reiterated an “overweight” rating and issued a $310.00 price target on shares of Amgen in a report on Thursday, January 2nd. Wells Fargo & Company reissued an “equal weight” rating on shares of Amgen in a research note on Wednesday, February 5th. Citigroup reissued a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, UBS Group reaffirmed a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $314.09.

Amgen Stock Up 0.9 %

NASDAQ:AMGN opened at $310.78 on Tuesday. The firm’s 50 day simple moving average is $281.80 and its 200 day simple moving average is $299.73. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a market cap of $166.95 billion, a PE ratio of 41.16, a P/E/G ratio of 2.63 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.06%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s payout ratio is currently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.